Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Receivables (2016 - 2025)

Cytokinetics (CYTK) has disclosed Change in Receivables for 10 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables changed N/A to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.1 million, a N/A change, with the full-year FY2025 number at $1.1 million, down 92.75% from a year prior.
  • Change in Receivables was $2.2 million for Q4 2025 at Cytokinetics, up from -$14.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $51.2 million in Q4 2021 to a low of -$50.8 million in Q1 2022.
  • A 5-year average of -$1.3 million and a median of -$449000.0 in 2024 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 9489.91% in 2021, then crashed 54103.19% in 2022.
  • Cytokinetics' Change in Receivables stood at $51.2 million in 2021, then crashed by 104.2% to -$2.1 million in 2022, then soared by 43.36% to -$1.2 million in 2023, then soared by 120.07% to $244000.0 in 2024, then surged by 782.38% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Change in Receivables are $2.2 million (Q4 2025), -$14.6 million (Q1 2025), and $244000.0 (Q3 2024).